Allogene Therapeutics Inc

Overview

Allogene Therapeutics Inc (Allogene Therapeutics) is a clinical stage biotechnology company. It develops allogeneic T-cell (CAR T) therapies for cancer. The company’s pipeline product includes UCART19, ALL0-501 and ALL0-501A an off-the shelf allogeneic CAR T therapy candidate for the treatment of hematological malignancies; BCMA, CD70 and DLL3 for solid tumors; and ALLO-647, an anti-CD52 monoclonal antibody used as lymphodepleting agent. Allogene Therapeutics develops products in the therapeutic areas of cancers and solid tumors. The company seeks to partner with other companies in the research and development of immuno-oncology therapies. Allogene Therapeutics is headquartered in South San Francisco, California, the US.
Key Stats
Address
210 E Grand Ave, South San Francisco, California
Headquarters

United States of America

Contact

1 650 4572700

No of Employees

285

Industry

Pharmaceuticals and Healthcare

Ticker Symbol & Exchange​

ALLO [NASD]

Net Income (2020)

$-250 m

-35.4% (2020 vs 2019)
Market Cap *

$3,408 m

EPS *

$-2.1

  *Note: Ratios based on the share price as of 6-October-2021, in absolute numbers and US$.

Peer Comparison

Key Parameters Allogene Therapeutics IncFate Therapeutics IncArvinas IncLyell Immunopharma Inc
Key Information
Headquarters United States of America United States of America United States of America United States of America
Headquarter City South San Francisco San Diego New Haven South San Francisco
Headquarter State/Province California California Connecticut California
No. of Employees 285 279 179 188
Entity Type Public Public Public Public

Products & Services

Allogene Therapeutics is involved in development and commercialization cancer treatment products.The key products under development offered by the company include the following:

Products
  • Products
  • Hematological Malignancies:
  • UCART19
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero

Employees

Name Position Board Since Age Biography
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2021 Regulatory Approval In August, the company secured the US FDA granted orphan-drug designation to ALLO-715 for the…
2020 Contracts/Agreements In March, the company entered into an agreement with MaxCyte to enable the advancement of…
2020 Contracts/Agreements In October, the company collaborated with the University of Texas MD Anderson Cancer Center to…
2020 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2020 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2019 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam

Locations


Allogene Therapeutics, B.V.

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
10 Feb 2021 Notch Therapeutics Raises USD85 Million in Series A Financing Venture Financing Lumira Capital Investment Management Inc; Samsara BioCapital LLC; Centre for Commercialization of Regenerative Medicine; Casdin Capital LLC; Amplitude Ventures Inc; Allogene Therapeutics Inc; EcoR1 Capital LLC Notch Therapeutics Inc
15 Dec 2020 Allogene Therapeutics and Overland Pharma Form Joint Venture Partnership Allogene Overland Biopharm Overland Pharmaceuticals; Allogene Therapeutics Inc
15 Dec 2020 Allogene Overland Biopharm Enters into Licensing Agreement with Allogene Therapeutics Licensing Agreement Allogene Overland Biopharm Allogene Therapeutics Inc
15 Oct 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
19 Sep 2019 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
06 Dec 2018 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit

Jobs Overview

44

Active Jobs

26

Posted

24

Closed

Job Trends

Latest Jobs

Job title Company Country
Scientist/Senior Associate Scientist, Analytical Development Allogene Therapeutics Inc United States
Associate Director, External Quality Allogene Therapeutics Inc United States
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar